Heron Therapeutics (HRTX) Resubmits NDA to FDA for HTX-011 for Treatment of Postoperative Pain

Go back to Heron Therapeutics (HRTX) Resubmits NDA to FDA for HTX-011 for Treatment of Postoperative Pain

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain

November 13, 2020 8:30 AM EST

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration (FDA) for HTX-011, an investigational agent for the management of postoperative pain.

The NDA for HTX-011 was resubmitted based on the outcome and final minutes of a Type A End-of-Review meeting with the FDA in September,... More